BOSTON ( TheStreet) -- Welcome back to another installment of the Biotech Stock Mailbag. The first email comes from Tom S., who writes:
"Any updated thoughts on Titan Pharmaceuticals (TTNP.OB)? I follow your articles so I know where you stand on Fanapt. What are your thoughts on Probuphine and Proneura? Titan just received funding and with whatever Fanapt royalties come its way the company should be solvent for some time. I believe Titan has three full-time employees, any chance it tries to ramp up to be a viable company or is it an inevitable sale?"
For those unfamiliar, Titan, like Vanda Pharmaceuticals (VNDA), receives a royalty payment based on sales of the schizophrenia drug Fanapt. Given my very skeptical outlook on Fanapt (see my negative comments to the next reader below) I don't see those monies amounting to much for Titan, although every little bit does help when you're as small as Titan is.
Probuphine is interesting. It's a small rod containing the opioid addiction drug buprenorphine that doctors implant just under the skin, usually in the arm. The rod slowly releases buprenorphine into a patient's bloodstream, giving a consistent steady dose of the drug for up to six months.Probuphine works. Results from an older phase III study were published last week in Journal of the American Medical Association and Titan is working on a confirmatory, phase III study. I expect this second study to be positive too because buprenorphine is known to be effective in treating opioid addiction and the technology used in the implantable rods has been around for some time. The issue with Probuphine is more commercial -- I think the market for the drug is very small. Nearly all opioid addicts treated with buprenorphine today take the drug orally on daily basis. Probuphine would likely only be used for those addicts who can't seem to stick with the routine of taking a daily buprenorphine pill or who constantly relapse back into their opioid or heroin addiction. If a patient suffers side effects from the medication, the implanted rod needs to be removed, which would be a hassle and something most doctors would want to steer away from. Very few, if any, implantable drugs have ever been commercially successful. Implantable birth control for women, for instance, was tried years ago but never caught on.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV